Cyclacel Pharmaceuticals (CYCC) Earnings Date, Estimates & Call Transcripts $0.23 0.00 (-0.52%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cyclacel Pharmaceuticals Earnings Summary Upcoming Earnings DateMay. 7Before Market OpensEstimatedConsensus EPS (Apr. 2) -$0.29 Actual EPS (Apr. 2) -$0.33 Missed By -$0.04 Actual Revenue (Apr. 2) $0.01MCyclacel Pharmaceuticals posted Q4 2024 earnings on April 2, 2025, reporting an EPS of -$0.33, which missed analysts' consensus estimates of -$0.29 by $0.04. Quarterly revenue was reported to be $0.01 million, below analysts' expectations of $0.01 million. Cyclacel Pharmaceuticals currently has a trailing EPS of -$3.50Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Press Release (8-K) Annual Report (10-K)CYCC Upcoming EarningsCyclacel Pharmaceuticals' Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Cyclacel Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCYCC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CYCC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cyclacel Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.29-$0.29-$0.29Q2 20251-$0.30-$0.30-$0.30Q3 20251-$0.30-$0.30-$0.30Q4 20251-$0.30-$0.30-$0.30FY 20254($1.19)($1.19)($1.19) Cyclacel Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/7/2025(Estimated)--------4/2/2025Q4 2024-$0.29-$0.33 -$0.04-$0.33$0.01M$0.01M11/12/2024--$0.54-$0.18+$0.36-$0.18$0.01M$0.01M8/14/2024Q2 2024-$0.83-$0.72+$0.11-$0.72$0.03M-5/14/2024Q1 2024-$4.93-$2.27+$2.66-$2.27-$0.03M3/19/2024Q4 2023-$6.35-$6.23+$0.12-$6.23-$0.03M11/13/2023Q3 2023-$5.70-$7.35 -$1.65-$0.49-$0.02M8/9/2023Q2 2023-$8.10-$6.60+$1.50-$0.44-$0.37M5/11/2023Q1 2023-$10.20-$7.05+$3.15-$0.47-- More Earnings Resources from MarketBeat Related Companies Kodiak Sciences Earnings Canopy Growth Earnings Esperion Therapeutics Earnings INmune Bio Earnings Inhibrx Earnings Actuate Therapeutics Earnings Cybin Earnings LifeVantage Earnings Molecular Partners Earnings DiaMedica Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? This page (NASDAQ:CYCC) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCC Stock Free CYCC Stock Alerts